Triple-negative breast cancer (TNBC) accounts for approximately 15–20% of all breast cancer cases and lacks the expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) [2]. This evidence concerns the gene PGR and triple-negative breast carcinoma.